Article thumbnail

Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab.

By S. Morteza Seyed Jafari, Laurence Feldmeyer and Robert E. Hunger

Abstract

The immune checkpoint inhibitors opened a new era for the treatment of melanoma. Nowadays, combined immune checkpoint inhibitors are administered to provide additive or synergistic effects on anti-melanoma immunity. The use of these drugs comes with serious adverse events related to excessive immune activation. Here, we present development of extragenital lichen sclerosus in a patient with metastatic malignant melanoma, during the combined therapy with checkpoint inhibitors

Topics: 610 Medicine & health
Publisher: 'Frontiers Media SA'
Year: 2020
DOI identifier: 10.3389/fonc.2020.573527
OAI identifier: oai:boris.unibe.ch:148365

Suggested articles


To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.